September 12, 2026
Investing

Food stocks fall as investors brace for increased scrutiny from RFK Jr.

A chip and snack food display at a convenience store in Miami Beach, Florida. Jeff Greenberg | Universal Images Group | Getty Images Processed food stocks tumbled on Friday as investors feared a crackdown under President-elect Donald Trump and ally Robert F. Kennedy Jr. Soda titans PepsiCo and Coca-Cola dropped more than 4% and 1.3%, […]

Read More
Investing

Wood says ARK Innovation fund shouldn’t be ‘huge slice of any portfolio’

Cathie Wood, CEO of Ark Invest, speaks during an interview on CNBC on the floor of the New York Stock Exchange on Feb. 27, 2023. Brendan McDermid | Reuters Cathie Wood is defending her underperforming ARK Innovation exchange-traded fund following a rocky stretch. “We have a volatile fund,” she told CNBC’s “Squawk Box” on Friday. […]

Read More
Investing

Friday's big stock stories: What’s likely to move the market in the next trading session

Stocks slid on Thursday as Fed Chair Jerome Powell signaled that policymakers don’t need to be in a hurry to cut rates. Here’s what’s on CNBC’s radar Friday. Source link

Read More
Investing

BlackRock expands tokenized money market fund to Polygon, other blockchains

The BlackRock logo is pictured outside the company’s headquarters in the Manhattan borough of New York City on May 25, 2021. Carlo Allegri | Reuters BlackRock has expanded its tokenized money market fund to include several more blockchains. The investment manager said Wednesday that its USD Institutional Digital Liquidity Fund (BUIDL) is now available to […]

Read More
Investing

David Einhorn to speak as the priciest market in decades gets even pricier postelection

David Einhorn speaking in New York City on April 3, 2024. Adam Jeffery | CNBC Hedge fund investor David Einhorn’s cautious stance all year made his performance suffer as he navigated what he believes is the priciest stock market of his career at Greenlight Capital. Einhorn’s hedge fund returned just 9% in 2024 through the […]

Read More
Investing

Hedge funds performed better under Democratic presidents than Republican ones, history shows

Traders work on the floor of the New York Stock Exchange.  NYSE There’s been a rush of enthusiasm on Wall Street regarding Donald Trump’s election win, but hedge funds actually generate more alpha when the White House is occupied by a Democrat president than a Republican one, according to HFR, collating data going back to […]

Read More
Investing

What’s likely to move the market

Traders work on the New York Stock Exchange floor on November 12, 2024 in New York City. Source: NYSE Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and last look at today. Sign up for free to receive it directly in your inbox. Here’s what CNBC TV’s producers […]

Read More
Investing

Trump is the most pro-stock market president in history, Wharton’s Jeremy Siegel says

The stock market could enjoy a bigger boost from President-elect Donald Trump than any previous administration thanks to his pro-business policies, according to Jeremy Siegel, finance professor at the Wharton School of the University of Pennsylvania. “President-elect Trump is the most pro-stock market president we have had in our history,” Siegel said Monday on CNBC’s “Squawk […]

Read More
Investing

Top Wall Street analysts like these dividend-paying stocks

The major averages have been on a sharp upward turn since Donald Trump won the presidential election last week, but investors who want to buffer their portfolio from future market shocks may want to add dividend stocks. To select the right dividend stocks, investors can consider the recommendations of top Wall Street analysts, who have […]

Read More
Investing

Caligan takes a stake in Verona Pharma, sees opportunity to generate more value

Rafael Henrique | SOPA Images | AP Company: Verona Pharma (VRNA) Business: Verona Pharma, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company’s product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes […]

Read More